Education
About Us
Working with TipRanks
Follow Us
eFFECTOR Therapeutics (EFTR)
OTHER OTC:EFTR
RESEARCH TOOLSreports
EFTR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.38
Previous CloseN/A
Volume10.00
Average Volume (3M)N/A
Market Cap
$1.41K
Enterprise ValueN/A
Total Cash (Recent Filing)$25.38M
Total Debt (Recent Filing)$20.25M
Price to Earnings (P/E)―
Beta-55.02
Next Earnings
May 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.31
Shares Outstanding4,704,409
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
eFFECTOR Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
4.62% Insiders
<0.01% Mutual Funds
1.31% Other Institutional Investors
98.69% Public Companies and
Individual Investors
EFTR FAQ
What was eFFECTOR Therapeutics’s price range in the past 12 months?
eFFECTOR Therapeutics lowest stock price was $0.03 and its highest was $0.38 in the past 12 months.
What is eFFECTOR Therapeutics’s market cap?
eFFECTOR Therapeutics’s market cap is $1.41K.
When is eFFECTOR Therapeutics’s upcoming earnings report date?
eFFECTOR Therapeutics’s upcoming earnings report date is May 13, 2025 which is 41 days ago.
How were eFFECTOR Therapeutics’s earnings last quarter?
Currently, no data Available
Is eFFECTOR Therapeutics overvalued?
According to Wall Street analysts eFFECTOR Therapeutics’s price is currently Overvalued.
Does eFFECTOR Therapeutics pay dividends?
eFFECTOR Therapeutics does not currently pay dividends.
What is eFFECTOR Therapeutics’s EPS estimate?
eFFECTOR Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eFFECTOR Therapeutics have?
eFFECTOR Therapeutics has 4,704,409 shares outstanding.
What happened to eFFECTOR Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eFFECTOR Therapeutics?
Currently, no hedge funds are holding shares in EFTR
Company Description
eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―